$4.35
10.69% today
Nasdaq, Apr 02, 09:17 pm CET
ISIN
US30068X1037
Symbol
XGN

Exagen Inc Stock price

$3.93
+0.87 28.43% 1M
+1.08 37.89% 6M
-0.17 4.15% YTD
+2.36 150.32% 1Y
-3.81 49.22% 3Y
-10.49 72.75% 5Y
-14.65 78.85% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.34 9.47%
ISIN
US30068X1037
Symbol
XGN
Sector

Key metrics

Market capitalization $70.34m
Enterprise Value $71.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.29
P/S ratio (TTM) P/S ratio 1.26
P/B ratio (TTM) P/B ratio 7.27
Revenue growth (TTM) Revenue growth 5.89%
Revenue (TTM) Revenue $55.64m
EBIT (operating result TTM) EBIT $-13.64m
Free Cash Flow (TTM) Free Cash Flow $-13.79m
Cash position $22.04m
EPS (TTM) EPS $-0.83
P/E forward negative
P/S forward 1.09
EV/Sales forward 1.11
Short interest 0.14%
Show more

Is Exagen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Exagen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

Buy
83%
Hold
17%

Financial data from Exagen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
56 56
6% 6%
100%
- Direct Costs 23 23
2% 2%
40%
33 33
12% 12%
60%
- Selling and Administrative Expenses 40 40
11% 11%
71%
- Research and Development Expense 5.38 5.38
10% 10%
10%
-12 -12
41% 41%
-21%
- Depreciation and Amortization 1.72 1.72
35% 35%
3%
EBIT (Operating Income) EBIT -14 -14
40% 40%
-25%
Net Profit -15 -15
36% 36%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Exagen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exagen Inc Stock News

Neutral
Seeking Alpha
22 days ago
Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Ma...
Neutral
GlobeNewsWire
22 days ago
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and fu...
Neutral
GlobeNewsWire
about one month ago
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the...
More Exagen Inc News

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Head office United States
CEO John Aballi
Employees 209
Founded 2002
Website www.exagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today